researchers estimated weight loss would be 20.7% for the 7.2 milligram group, 17.5% for the 2.4 milligram group and 2.4% for the placebo group. Novo Nordisk announced the study results on Jan. 17 ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.

Novo Nordisk said that patients taking a higher dose of its blockbuster Wegovy obesity shot lost more weight than those on a lower dose without experiencing an increase in side effects ...

Jan 17 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe ... vice-president Martin Holst Lange said: “Results from STEP UP further strengthen the ...

Novo Nordisk (NVO) stock slipped after ate-stage trial data for a higher-dose version of its popular obesity therapy, ...

Results of early-stage trial of injectable ... obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results ...

also includes Wegovy and Zepbound. GLP-1s were developed to treat diabetes, but they have become popular weight-loss medications. MORE: In Kensington, outreach workers give out food, clothing and ...